5 completed, 2 recruiting, 1 terminated. 8 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 5, Recruiting 2, Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow The Parkinson Study Group: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD) Adalimumab, Placebo - REM Sleep Behavior Disorder | Phase 2 | Recruiting | Yale University | 108 | 2026-08-17 | 2026-10-08 |
| Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease HBI-002, Vehicle (placebo) - Parkinson Disease | Phase 2 | Recruiting | Hillhurst Biopharmaceuticals, Inc. | 36 | 2026-06-30 | 2026-09-21 |
| Auricular Muscle Zone Stimulation for Parkinson Disease Earstim - Active Stimulation, Earstim - Sham Stimulation - Parkinson Disease | Phase 2 | Completed | Stoparkinson Healthcare Systems LLC | 38 | 2021-05-01 | 2022-01-11 |
| A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease UCB0599, Placebo - Early-stage Parkinson's Disease | Phase 2 | Completed | UCB Biopharma SRL | 496 | 2020-12-30 | 2025-10-31 |
| Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease Isradipine CR 5mg, Isradipine CR 10mg, Isradipine CR 20mg - Parkinson Disease | Phase 2 | Completed | Northwestern University | 99 | 2009-07-01 | 2013-04-17 |
| Safety of Urate Elevation in Parkinson's Disease Placebo, inosine - Parkinson Disease | Phase 2 | Completed | The Parkinson Study Group | 75 | 2009-06-01 | 2014-06-05 |
| POETRY: Study of Estrogen Replacement Therapy in Postmenopausal Women With Parkinson's Disease Premarin ® - Parkinson's Disease | Phase 2 | Completed | The Parkinson Study Group | 23 | 2003-10-01 | 2008-01-08 |
| Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease CEP-1347 10mg, CEP1347 25mg, CEP-1347 50mg - Parkinson Disease | Phase 2 / Phase 3 | Terminated | Cephalon | 806 | 2002-03-01 | 2012-05-10 |
Parkinson Disease (7) · REM Sleep Behavior Disorder (1) · Synucleinopathies (1)
3,9-bis((ethylthio)methyl)-K-252a (1) · Adalimumab (1) · Estrogens, Conjugated (USP) (1) · Inosine (1) · Isradipine (1)
United States (8) · Canada (4) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · Puerto Rico (1) · Spain (1) · United Kingdom (1)
Jesse Cedarbaum, MD (1) · Lisa M Shulman, MD (1) · Michael A Schwarzschild, MD, PhD (1) · Stanley Fahn, MD (1) · Tanya Simuni, MS (1) · Yusuf O Cakmak, MD, PhD (1)
PMID 17881719, PMID 18413464, PMID 24366103, PMID 31484712, PMID 37460603
R01AG095016 (1)